Neurocrine to Acquire Soleno Therapeutics via Tender

Neurocrine Biosciences, through a wholly owned subsidiary, Sigma Merger Sub, has filed a Schedule TO tender offer statement related to a planned tender offer for all outstanding shares of Soleno Therapeutics, Inc. common stock.

The tender offer is contemplated under an Agreement and Plan of Merger dated April 5, 2026. The filing references Soleno common stock with a $0.001 par value and CUSIP 834203309. The statement is tied to a planned tender offer followed by a subsequent merger, with completion subject to conditions in the merger agreement.